Lenalidomid Basics (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering its substrate specificity. This leads to the targeted degradation of transcription factors such as Ikaros and Aiolos, which modulates cytokine production, inhibits angiogenesis, and enhances immune‑mediated tumor cell killing, thereby exerting antitumor effects.

The specific dose of Lenalidomid Basics is determined individually by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers follow approved dosing guidelines and adjust the regimen as needed during treatment.

Lenalidomid Basics is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception before, during, and after treatment. Limited data exist for breastfeeding, and the drug is generally not recommended while nursing due to potential exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomid Basics. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide, thalidomide, and pomalidomide belong to the same immunomodulatory drug class but differ in potency, side‑effect profiles, and approved indications. Lenalidomide is generally more potent than thalidomide and has a lower incidence of peripheral neuropathy, while pomalidomide is used after lenalidomide failure and may have higher hematologic toxicity. Choice depends on disease stage, prior therapy, and patient tolerance.

Store Lenalidomid Basics at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Lenalidomid Basics is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed. Adherence to the prescribed schedule is essential for optimal therapeutic effect.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding; venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism; secondary primary malignancies; and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these events.

Lenalidomid Basics should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with severe hepatic impairment, or those receiving live vaccines. Caution is also advised for patients with uncontrolled infections or significant cardiac disease, and the drug should be avoided in anyone for whom the risk‑benefit balance is unfavorable.